Sermorelin dosage: childhood growth, mL and units
The figures below describe what particular studies gave their subjects. A dose decision requires a licensed clinician’s assessment of the individual.
Sermorelin dosage for children and height growth
The historical childhood growth work examined a defined problem: growth hormone deficiency before puberty. The first-year height-growth trial used daily subcutaneous sermorelin at 30 micrograms per kilogram. “Subcutaneous” means under the skin. Height velocity rose from about 4.1 to roughly 7-8 centimeters per year.
A separate study of growth-hormone-deficient children used a single daily subcutaneous 30 micrograms/kg amount for 12 to 24 months. Several responders formed GHRH antibodies, without an apparent interference with growth; no side effects or changes in glucose and lipid levels were noted.
For kids outside those study populations, these papers cannot select a sermorelin dosage for height growth. The reason for slow growth, the pituitary’s ability to respond and the individual assessment all matter. I place the diagnosis ahead of any amount lifted out of its study.
Study amounts in older adults
In the older-men trial, the study amounts were 0.5 milligrams and 1 milligram, given subcutaneously twice daily for 14 days. The men’s mean age was 68. The larger amount produced greater GH and IGF-1 responses, with no change in fasting glucose.
The 16-week study in older women and men used 10 micrograms/kg nightly of [Nle27]GHRH-(1-29)-NH2. That is a modified analogue. Its amount and duration describe its own experiment.
Micrograms and milligrams measure drug mass; a milligram equals one thousand micrograms. The differing units can make figures look more alike, or more different, than they are. These protocols provide historical context, without deciding an adult treatment amount.
Intravenous diagnostic and pharmacokinetic studies
The pharmacokinetic study in 30 healthy men tested intravenous amounts of 0.25-2 micrograms/kg. Significant GH release occurred at 0.25 micrograms/kg, with maximal release at 1-2 micrograms/kg. The study measured an acute response after delivery directly into a vein.
A childhood stimulation test used a single intravenous 1 microgram/kg amount to examine the pituitary response. That diagnostic purpose differs from the repeated treatment studied for height growth. I would never use the speed of that acute response to estimate a lasting health benefit.
Sermorelin dosage in mL and units
An amount of sermorelin and a volume of liquid answer different questions. Milligrams and micrograms describe drug mass; mL describes liquid volume. Syringe unit marks alone leave the drug concentration unspecified.
Consequently, these papers provide no universal sermorelin dosage in mL or units for a pharmacy preparation. A preparation’s concentration and dispensing instructions are needed to interpret its volume markings. This page has no mixing recipe or syringe conversion; those particulars require the dispensing pharmacy and the prescribing clinician.
The distinction also applies to sermorelin acetate dosage. “Acetate” describes the salt form used to prepare the drug, while the study’s route and stated amount still need to be identified.
Routes, tablets and storage
Through the nose, only 3-5% of native GHRH(1-29) reached the circulation in the pharmacokinetic work. A separate route-comparison study in healthy men used the modified [Nle27] analogue: relative to intravenous delivery, it required a tenfold higher subcutaneous amount and a thirtyfold higher intranasal amount for the response studied. Those differences illustrate how delivery changes exposure.
The injection studies cannot establish the performance of a swallowed tablet or a lozenge dissolved in the mouth. Digestion and passage across the mouth’s lining introduce separate absorption questions.
Sermorelin acetate is supplied as freeze-dried powder because aqueous peptide preparations can degrade. Reconstituted preparations are typically refrigerated, and sterile compounding standards govern pharmacy preparation. Preparation-specific handling and storage details come from the dispensing pharmacy.
The safety findings and human studies provide the outcomes that go with these amounts. For dosage, I care about whether the measured benefit justified the intervention in its particular population; the number alone cannot settle that.